News Release: Hemedex, Inc. Launches Redesigned Website

Posted by on Jul 10, 2013 in News Releases

News Release: Hemedex, Inc. Launches Redesigned Website

CAMBRIDGE, Mass. (July 15, 2013) – Hemedex, Inc. today announced the launch of its new corporate website, www.hemedex.com. The new website offers user-friendly features and clear navigation, a media gallery including images and videos of the Hemedex product line, as well as a literature library.

One of the key additions to the new website is the Clinical Section.

“During the development of our new website, a key objective was to design it in a way to educate and inform our target audience on the benefits of quantifying perfusion and the positive impact perfusion monitoring can have on patient care,” said H. Frederick Bowman, CEO.

The clinical section provides visitors with an enhanced insight into the technique used by the Bowman Perfusion Monitor® and QFlow 500™ Perfusion Probe to measure perfusion. The Hemedex product line also includes single and multi-lumen cranial bolt kits.

Hemedex is creating a MyHemedex Secure Portal that will provide information for customers, such as training videos and documents for their team, and other support information.

In addition, the website will assist Hemedex in taking the next step in developing its U.S. and international distribution network by providing essential tools needed to be successful.

The website will evolve as news, events, and manuscripts are available and as the technology is adopted into new markets. Hemedex invites customers and investors to peruse the new website to learn about its innovative technology in the medical device industry.

About Hemedex, Inc.:

Hemedex, Inc. manufactures patient monitoring technology, the Bowman Perfusion Monitor®, for quantifying tissue blood flow. The Company’s patented technology provides clinicians with a powerful tool, which can provide an early warning of compromised blood flow and help target appropriate therapies rapidly and accurately. Data from the Bowman Perfusion Monitor helps guide physicians in implementing effective treatments quickly, creating the potential to improve patient outcomes and lower costs. Hemedex’s technology addresses unmet needs in many clinical areas such as neurocritical care (e.g., TBI, SAH), neurosurgery (e.g., TAO, EC-IC Bypass, Moya Moya), reconstructive surgery and organ transplantation, among others.  For more information, visit www.hemedex.com.

Communications Team
Hemedex Inc.
sblair@hemedex.com
617 577 1759 X 46